A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Cancer metastases; Malignant melanoma; Merkel cell carcinoma; Solid tumours
- Focus Therapeutic Use
- 09 Apr 2024 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Feb 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.